(Total Views: 505)
Posted On: 05/15/2025 9:12:31 AM
Post# of 154881
Re: KenChowder #152982
Ken, good catch. Cytodyn PR person should have caught this!
In CytoDyn’s latest cancer data, 5 out of 7 women treated with Leronlimab + an immune checkpoint inhibitor (ICI) survived. But here’s the real shocker: 100% of those whose PD-L1 levels increased after receiving high-dose Leronlimab survived. The 2 who didn’t make it? They didn’t show the PD-L1 jump. That means this isn’t luck — it’s biology. Leronlimab primes the immune system by turning tumors “hot” (PD-L1↑), then the ICI finishes the job. These were late-stage, heavily pre-treated patients — and yet, with the right combo, every single one survived. This isn’t just a signal. It’s a strategy. And it means one thing: More than 88% CAN BE SAVED.
In CytoDyn’s latest cancer data, 5 out of 7 women treated with Leronlimab + an immune checkpoint inhibitor (ICI) survived. But here’s the real shocker: 100% of those whose PD-L1 levels increased after receiving high-dose Leronlimab survived. The 2 who didn’t make it? They didn’t show the PD-L1 jump. That means this isn’t luck — it’s biology. Leronlimab primes the immune system by turning tumors “hot” (PD-L1↑), then the ICI finishes the job. These were late-stage, heavily pre-treated patients — and yet, with the right combo, every single one survived. This isn’t just a signal. It’s a strategy. And it means one thing: More than 88% CAN BE SAVED.
(9)
(0)
